Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics-Reference-Cited by-同舟云学术

Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics

Published:2021-12-24 Issue:52 Volume:7 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Gerckens Michael¹^ORCID,Schorpp Kenji²^ORCID,Pelizza Francesco³^ORCID,Wögrath Melanie¹⁴,Reichau Kora⁵⁶^ORCID,Ma Huilong⁵⁶,Dworsky Armando-Marco¹⁴,Sengupta Arunima¹^ORCID,Stoleriu Mircea Gabriel¹⁴⁷^ORCID,Heinzelmann Katharina⁸⁹,Merl-Pham Juliane¹⁰^ORCID,Irmler Martin¹¹,Alsafadi Hani N.⁴⁹¹²^ORCID,Trenkenschuh Eduard¹³,Sarnova Lenka¹⁴,Jirouskova Marketa¹⁴,Frieß Wolfgang¹³^ORCID,Hauck Stefanie M.¹⁰^ORCID,Beckers Johannes¹¹¹⁵¹⁶^ORCID,Kneidinger Nikolaus⁴¹⁷^ORCID,Behr Jürgen⁴⁷¹⁷^ORCID,Hilgendorff Anne¹⁴,Hadian Kamyar²^ORCID,Lindner Michael⁴⁷¹⁸^ORCID,Königshoff Melanie⁸⁹^ORCID,Eickelberg Oliver⁸^ORCID,Gregor Martin¹⁴^ORCID,Plettenburg Oliver⁵⁶¹⁹^ORCID,Yildirim Ali Önder¹^ORCID,Burgstaller Gerald¹⁴^ORCID

Affiliation:

1. Institute of Lung Biology and Disease (ILBD) and Comprehensive Pneumology Center (CPC), Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany.

2. Assay Development and Screening Platform, Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.

3. Chemical and Process Engineering, Strathclyde University, Glasgow, Scotland, UK.

4. CPC-M bioArchive, Helmholtz Zentrum München, Comprehensive Pneumology Center Munich DZL/CPC-M, Munich, Germany.

5. Institute of Medicinal Chemistry, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany.

6. Leibniz Universität Hannover, Institute of Organic Chemistry and Center for Biomolecular Drug Research (BMWZ), Hannover, Germany.

7. Asklepios Fachkliniken Munich-Gauting, Munich, Germany.

8. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

9. Comprehensive Pneumology Center (CPC), Research Unit Lung Repair and Regeneration, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany.

10. Research Unit Protein Science, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany.

11. Institute of Experimental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany.

12. Wallenberg Center for Molecular Medicine (WCMM), Department of Experimental Medical Sciences, Lund University, Lund, Sweden.

13. Department of Pharmacy–Center for Drug Research, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximillians University of Munich, Munich, Germany.

14. Laboratory of Integrative Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.

15. German Center for Diabetes Research (DZD e.V.), 85764 Neuherberg, Germany.

16. Chair of Experimental Genetics, Technische Universität München, 85354 Freising, Germany.

17. Department of Internal Medicine V, Ludwig-Maximillians University of Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.

18. Paracelsus Medical Private University, Salzburg, Austria.

19. Institute for Lung Health (ILH), Justus Liebig University, Giessen, Germany.

Abstract

Innovative high-content screening platform identified N -(2-butoxyphenyl)-3-(phenyl)acrylamides as novel antifibrotics.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference70 articles.

1. Mechanisms of fibrosis: therapeutic translation for fibrotic disease

2. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer

3. Fibrosis — A Common Pathway to Organ Injury and Failure